PRAX News and Press, Praxis Precision Medicines Inc. From 03/03/23

Praxis Precision Medicines PRAX -49% after mid-stage data for movement disorder candidate . Veru VERU -34% after Veru COVID respiratory treatment sabizabulin declined authorization by FDA . Cidara Therapeutics ( CDTX ) -17% on launching concurrent but separa...

Despite its plans to advance ulixacaltamide, a candidate for movement disorder essential tremor (ET), towards Phase 3 development, Praxis Precision Medicines ( NASDAQ: PRAX ) lost ~42% pre-market Friday after announcing mixed results from a Phase 2 trial. Citing topline data from ...

Based upon observed efficacy and safety profile, Praxis intends to engage with the FDA in an end of Phase 2 meeting and initiate a ulixacaltamide Phase 3 study for the treatment of essential tremor in 2H23 Ulixacaltamide demonstrated improvement in modified Activities of Daily Living (m...

Summary Praxis Precision Medicines' ulixacaltamide (PRAX-944) is a potent and selective small molecule T-type Ca2+ channel blocker being developed for the potential treatment of essential tremor. ET is a common movement disorder affecting 4% of adults > 40. Current treatments like be...

Praxis Precision Medicines press release ( NASDAQ: PRAX ): Q4 GAAP EPS of -$0.87 misses by $0.08 . As of December 31, 2022, Praxis had $100.5 million in cash, cash equivalents and marketable securities, compared to $275.9 million in cash, cash equivalents and marketable securi...

Ulixacaltamide (PRAX-944) Phase 2b Essential1 study topline results for essential tremor expected in 1Q23; Praxis to enter quiet period following market close on Thursday, February 9 Topline results expected for each of three clinical-stage epilepsy programs in 2023 – PRAX-222 fi...

BOSTON, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company, and UCB (EURONEXT BRUSSELS: UCB), a global biopharmaceutical company, today announced a strategic collaboration, based upon Praxis’ PRAX-020 program, ...

BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibitio...

BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibitio...

Praxis Precision Medicines press release ( NASDAQ: PRAX ): Q3 GAAP EPS of -$0.96 misses by $0.04 . $123.7 million in cash, cash equivalents and marketable securities, compared to $275.9 million in cash. The Company’s cash, cash equivalents and marketable sec...